中国临床药理学杂志2017，Vol.33Issue(14)：1307-1310,4.DOI:10.13699/j.cnki.1001-6821.2017.14.006
犀黄丸联合伊立替康和顺铂治疗局限期小细胞肺癌的临床研究
Clinical trial of Xihuang pill combined with irinotecan and cisplatin chemotherapy in the treatment of limited stage small cell lung cancer
摘要
Abstract
Objective To evaluate the efficacy and safety of Xihuang pill combined with irinotecan plus cisplatin chemotherapy in the treatment of limited stage small cell lung cancer.Methods A total of 100 patients with limited stage small cell lung cancer were divided into control group (n =50) and treatment group (n =50).The control group was treated with irinotecan hydrochloride injection 60 mg · m-2iv on the 1st and 8th day of each treatment cycle and cisplatin injection 75 mg · m-2iv on the 1 st day for each treatment cycle.Treatment group was treated with 6 g of Xihuang pill,qd,on the basis of control group.All groups were treated for 4 treatment cycles (21 d per treatment cycle).Clinical efficacy,serum lactate dehydrogenase (LDH),tissue polypeptide specific antigen (TPS),gastrin releasing peptide (GRP),neuron specific enolase (NSE),overall survival rate and adverse reaction were compared with control group after treatment.Results After treatment,the clinical efficacy in treatment group and control group were 88.00％ (44/50 cases) and 60.00％ (30/50 cases),with significant difference(P ＜ 0.05).In control group and treatment group,LDH were(301.29 ±45.37),(232.78 ±33.57)U · L-1,TPS were (57.29 ±6.39),(48.39 ±4.90)U · L-1,ProGRP were (57.39 ± 8.79),(22.9 1 ± 4.70) U · L-1,NSE were respectively (19.29 ± 2.91),(13.29 ± 1.89) μg · L-1,CEA were(7.38 ± 1.61),(5.24 ±0.87) μg · L-1,SCC were (3.29 ±0.72),(2.12 ±0.34) ng · L-1,CYFR21-1 were(4.49 ±0.73),(2.40 ±0.38)ng · L-1,the difference were statistically significant (P ＜0.05).Adverse drug reactions in treatment group were nauseous (3 cases) and alopecia (2 cases),and the adverse drug reaction rate was 10.00％ (5/50 cases).The adverse drug reactions in control group were nauseous (3 cases),headache (2 cases) and alopecia (2 cases),the adverse drug reaction rate was 14.00％ (7/50 cases).There was no statistically difference in adverse drug reactions between the two groups (P ＞ 0.05).A total of 4 patients were dead in the treatment group (survival rate 92.00％),while 15 patients were dead in control group (survival rate was 70.00％),with significant difference (P ＜ 0.05).Conclusion The Xihuang pill combined with irinotecan plus cisplatin chemotherapy exerted considerable efficacy and high safety in the treatment of limited stage small cell lung cancer.关键词
犀黄丸/伊立替康/顺铂/局限期小细胞肺癌Key words
Xihuang pill/irinotecan/cisplatin/limited stage small cell lung cancer分类
医药卫生引用本文复制引用
岑浩锋..犀黄丸联合伊立替康和顺铂治疗局限期小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(14):1307-1310,4.基金项目
浙江省医药卫生计划基金资助项目(2011RCA016) （2011RCA016）
